SEC Company Response from Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Aug 14, 2015
Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: Aug. 14, 2015 · CIK: 0000894158 · Accession: 0001144204-15-050005
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-206267
Letter
August 14, 2015
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Jeffrey P. Riedler
Assistant Director
Re: Synthetic Biologics, Inc.
Registration Statement on Form S-3
Filed August 10, 2015
File No. 333-206267
To whom it may concern:
Synthetic Biologics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it may become effective by 5:00 p.m. Eastern Daylight Time on
August 18, 2015 or as soon thereafter as reasonably practicable.
In making this request, the Company acknowledges that: (i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it will not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
SYNTHETIC BIOLOGICS, INC.
By: /s/ Steven A. Shallcross
Steven A. Shallcross, Chief Financial Officer
Show Raw Text
CORRESP
1
filename1.htm
August 14, 2015
VIA EDGAR
United States Securities
and
Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Attention: Jeffrey P. Riedler
Assistant
Director
Re: Synthetic Biologics, Inc.
Registration Statement
on Form S-3
Filed August 10, 2015
File No. 333-206267
To whom it may concern:
Synthetic Biologics,
Inc. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement
so that it may become effective by 5:00 p.m. Eastern Daylight Time on
August 18, 2015 or as soon thereafter as reasonably practicable.
In making this request,
the Company acknowledges that: (i) should the Securities and Exchange Commission (the “Commission”) or the staff, acting
pursuant to delegated authority, declare the filing effective, it will not foreclose the Commission from taking any action with
respect to the filing; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the
filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in
the filing; and (iii) the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding
initiated by the Commission or any person under the federal securities laws of the United States.
SYNTHETIC BIOLOGICS, INC.
By:
/s/ Steven A. Shallcross
Steven A. Shallcross, Chief Financial Officer